Official Title
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
Brief Summary

The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and fibrosis in patients with a variety of medical conditions. The investigators hypothesize that using nebulized and/or intravenous purified (acellular) amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.

Recruiting
SARS CoV-2 Infection

Biological: Human Amniotic Fluid
Administration of amniotic fluid in SARS-CoV-2 positive patients
Treatment

Eligibility Criteria

Inclusion Criteria:

- 1. Age ≥18

- 2. Hospitalized and symptomatic (cough, fevers, SOB, or sputum production)

- 3. SARS CoV-2 laboratory positive obtained within 14 days of enrollment

Exclusion Criteria:

- 1. None

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
United States
Locations

University of Utah Health
Salt Lake City, Utah, 84132

Recruiting

Investigator: Craig Selzman, MD
Contact: 801-581-5311
craig.selzman@hsc.utah.edu

Contacts

Craig Selzman, MD
(801) 581-5311
craig.selzman@hsc.utah.edu

Joseph Tonna, MD
(801) 581-5311
joseph.tonna@hsc.utah.edu

Craig Selzman, MD
Principal Investigator
University of Utah

University of Utah
NCT Number
Keywords
Amniotic fluid
Respiratory failure
Critical illness
MeSH Terms
Respiratory Insufficiency